Palbociclib: an evidence-based review of its potential in the treatment of breast cancer.

Breast Cancer (Dove Med Press) · 2014 · PMC4128689 · PMID 25177151

Europe PMC DOI

hedged sentence

0.2105

closest p · 4.2× alpha

0.2105

boldest claim

The sentences

a nonsignificant trendP =0.2105not close (p > 0.1)

An interim analysis of overall survival, based on 61 patients, showed a nonsignificant trend in favor of the combination (37.5 months versus 33.3 months, respectively; HR 0.813; P =0.2105), these data were immature, and final analysis is outstanding.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.